Clinical Trial Update: Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating concurrent sorafenib with IMRT for advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Hepatocellular Carcinoma, Radiotherapy, Sorafenib | Phase 2 | Status: COMPLETED